Citadel Advisors
KPTI icon

Citadel Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Citadel Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.44M Buy
258,200
+225,700
+694% +$1.72M ﹤0.01% 6813
2025
Q4 		$239K Sell
32,500
-13,200
-29% -$80.7K ﹤0.01% 10657
2025
Q3 		$299K Buy
45,700
+29,476
+182% +$159K ﹤0.01% 10381
2025
Q2 		$69.9K Buy
16,224
+12,646
+353% +$62K ﹤0.01% 11590
2025
Q1 		$13.4K Buy
3,578
+1,425
+66% +$12.2K ﹤0.01% 13402
2024
Q4 		$21.8K Sell
2,153
-280
-12% -$3.38K ﹤0.01% 13123
2024
Q3 		$30.3K Buy
2,433
+786
+48% +$9.77K ﹤0.01% 12429
2024
Q2 		$21.4K Buy
1,647
+240
+17% +$3.97K ﹤0.01% 12573
2024
Q1 		$31.9K Buy
1,407
+914
+185% +$16K ﹤0.01% 12637
2023
Q4 		$6.4K Sell
493
-287
-37% -$3.87K ﹤0.01% 13353
2023
Q3 		$15.7K Sell
780
-1,387
-64% -$31.1K ﹤0.01% 12815
2023
Q2 		$58.2K Buy
2,167
+54
+3% +$2.33K ﹤0.01% 11628
2023
Q1 		$123K Sell
2,113
-3,627
-63% -$179K ﹤0.01% 10957
2022
Q4 		$293K Buy
5,740
+513
+10% +$35.6K ﹤0.01% 9373
2022
Q3 		$428K Sell
5,227
-420
-7% -$31.4K ﹤0.01% 8805
2022
Q2 		$382K Sell
5,647
-1,546
-21% -$142K ﹤0.01% 9239
2022
Q1 		$795K Sell
7,193
-63,147
-90% -$7.87M ﹤0.01% 8235
2021
Q4 		$6.79M Buy
70,340
+5,033
+8% +$502K ﹤0.01% 3778
2021
Q3 		$5.7M Buy
65,307
+500
+0.8% +$51.9K ﹤0.01% 4053
2021
Q2 		$10M Buy
64,807
+56,540
+684% +$8.21M ﹤0.01% 3063
2021
Q1 		$1.3M Buy
8,267
+1,674
+25% +$353K ﹤0.01% 7452
2020
Q4 		$1.53M Sell
6,593
-3,014
-31% -$698K ﹤0.01% 5928
2020
Q3 		$2.1M Buy
9,607
+5,980
+165% +$1.46M ﹤0.01% 4621
2020
Q2 		$1.03M Sell
3,627
-240
-6% -$71K ﹤0.01% 5777
2020
Q1 		$1.11M Buy
3,867
+347
+10% +$95.7K ﹤0.01% 5145
2019
Q4 		$1.01M Sell
3,520
-1,187
-25% -$258K ﹤0.01% 5556
2019
Q3 		$679K Buy
4,707
+3,434
+270% +$466K ﹤0.01% 6234
2019
Q2 		$114K Sell
1,273
-594
-32% -$47.7K ﹤0.01% 8488
2019
Q1 		$164K Sell
1,867
-140
-7% -$15.5K ﹤0.01% 8339
2018
Q4 		$282K Buy
2,007
+460
+30% +$77.6K ﹤0.01% 7375
2018
Q3 		$395K Buy
1,547
+640
+71% +$177K ﹤0.01% 7095
2018
Q2 		$231K Sell
907
-226
-20% -$55.9K ﹤0.01% 7639
2018
Q1 		$228K Buy
+1,133
New +$226K ﹤0.01% 7150
2016
Q1 		– Sell
-180
Closed -$36K – 7396
2015
Q4 		$36K Sell
180
-133
-42% -$28.8K ﹤0.01% 7552
2015
Q3 		$49K Buy
313
+186
+146% +$49.7K ﹤0.01% 7597
2015
Q2 		$52K Buy
127
+20
+19% +$8.64K ﹤0.01% 7632
2015
Q1 		$49K Sell
107
-186
-63% -$80.2K ﹤0.01% 7392
2014
Q4 		$165K Buy
293
+53
+22% +$30.1K ﹤0.01% 6187
2014
Q3 		$126K Buy
+240
New +$135K ﹤0.01% 6193

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citadel Advisors's KPTI Position: Q1 2026 in Review

Citadel Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 31,709 shares — an estimated $242K sold.

Citadel Advisors first reported a position in KPTI in Q2 2014 and held it in 43 quarters. The position peaked at $28.9M in Q1 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Citadel Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 31,709 Karyopharm Therapeutics shares in Q1 2026, an estimated $242K.
  • Citadel Advisors first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 43 quarters.
  • Citadel Advisors's Karyopharm Therapeutics position peaked at $28.9M in Q1 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.